As at Jun 3, 2026, the CORT stock has a price-to-earnings ratio of 157.93. This is based on the current EPS of $0.46 and the stock price of $72.65 per share. An increase of 138% has been recorded in the PE ratio compared to the average of 66.4 of the past four quarters.
The mean historical PE ratio of Corcept Therapeutics over the last ten years is 50.54. The current 157.93 price-to-earnings ratio is 212% more than the historical average. In the past ten years, CORT's PE ratio reached its highest point in the Jun 2016 quarter at 546, with a price of $5.46 and an EPS of $0.01. The Sep 2018 quarter saw the lowest point at 10.54, with a price of $14.02 and an EPS of $1.33.
Maximum annual increase: 92.62% in 2020
Maximum annual decrease: -84.73% in 2017
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 36.63 | -1.88% | $34.8 | $0.95 |
| 2024 | 37.33 | 17.24% | $50.39 | $1.35 |
| 2023 | 31.84 | 48.92% | $32.48 | $1.02 |
| 2022 | 21.38 | 4.75% | $20.31 | $0.95 |
| 2021 | 20.41 | -28.21% | $19.8 | $0.97 |
| 2020 | 28.43 | 92.62% | $26.16 | $0.92 |
| 2019 | 14.76 | -28.18% | $12.1 | $0.82 |
| 2018 | 20.55 | 29.73% | $13.36 | $0.65 |
| 2017 | 15.84 | -84.73% | $18.06 | $1.14 |
| 2016 | 103.71 | N/A | $7.26 | $0.07 |
| 2015 | N/A | N/A | $4.98 | -$0.06 |
| 2014 | N/A | N/A | $3 | -$0.31 |
| 2013 | N/A | N/A | $3.21 | -$0.46 |
| 2012 | N/A | N/A | $1.43 | -$0.41 |
| 2011 | N/A | N/A | $3.42 | -$0.39 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 87.63 | 139.23% | $40.31 | $0.46 |
| Dec 2025 | 36.63 | -55.93% | $34.8 | $0.95 |
| Sep 2025 | 83.11 | 42.68% | $83.11 | $1 |
| Jun 2025 | 58.25 | -35.23% | $73.4 | $1.26 |
| Mar 2025 | 89.94 | 140.93% | $114.22 | $1.27 |
| Dec 2024 | 37.33 | 9.7% | $50.39 | $1.35 |
| Sep 2024 | 34.03 | 27.79% | $46.28 | $1.36 |
| Jun 2024 | 26.63 | 21.6% | $32.49 | $1.22 |
| Mar 2024 | 21.9 | -31.22% | $25.19 | $1.15 |
| Dec 2023 | 31.84 | 2.84% | $32.48 | $1.02 |
| Sep 2023 | 30.96 | 23.84% | $27.25 | $0.88 |
| Jun 2023 | 25 | 1.58% | $22.25 | $0.89 |
| Mar 2023 | 24.61 | 15.11% | $21.66 | $0.88 |
| Dec 2022 | 21.38 | -9.94% | $20.31 | $0.95 |
| Sep 2022 | 23.74 | 1.84% | $25.64 | $1.08 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of CORT is above its 3, 5 and 10-year historical averages.
Corcept Therapeutics's P/E of 157.93 is above the Healthcare sector, the industry and its peers average.
When compared to its peer stocks LLY and JNJ, CORT's PE ratio is higher. Corcept Therapeutics's PE ratio is trading above the peer group average of 27.16.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BMY Bristol Myers Squibb Co | 15.86 | $115.6B |
| PFE Pfizer Inc | 19.61 | $146.42B |
| NVS Novartis AG | 21.14 | $283.17B |
| JNJ Johnson & Johnson | 26.13 | $549.06B |
| MRK Merck & Co Inc | 33.74 | $297.47B |
| LLY ELI LILLY & Co | 39.88 | $1.06T |
| BMRN Biomarin Pharmaceutical Inc | 40.31 | $10.91B |
| CORT Corcept Therapeutics Inc | 162.76 | $8.04B |
| ESPR Esperion Therapeutics Inc | N/A | $805.76M |
| MNKD Mannkind Corp | N/A | $1.09B |
The price to earnings ratio for CORT stock is 157.93 as of Jun 3, 2026.
Over the last 3 years, the average PE ratio for CORT stock is 46.94.
Over the last 5 years, the average PE ratio for CORT stock is 37.36.
In the last ten years, the Jun 2016 quarter recorded the highest quarterly PE ratio at 546.
CORT's current price to earnings ratio is 212% above its 10-year historical average.
CORT's PE ratio of 157.93 is considered high because the company's stock price is trading at a higher multiple of earnings.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jun 3, 2026), Corcept Therapeutics's stock price is $72.65. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.46. Therefore, Corcept Therapeutics's price to earnings ratio for today is 157.93. PE RATIO(157.93) = STOCK PRICE($72.65) / TTM EPS($0.46)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.